Univ of TX MD Anderson Cancer Cntr Primary
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Weiss, Jill
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
NCT05838768: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Recruiting
1
327
Europe, Japan, US, RoW
HRO761, pembrolizumab, irinotecan
Novartis Pharmaceuticals
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
05/29
05/29
Foote, Michael Bonner
NCT05838768: Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Recruiting
1
327
Europe, Japan, US, RoW
HRO761, pembrolizumab, irinotecan
Novartis Pharmaceuticals
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
05/29
05/29

Download Options